| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 1,000 | 5,000 | 15,000 | 0 |
| Sales Growth | -100.00% | -80.00% | -66.67% | unch | unch |
| Net Income | -41,520 | -59,690 | -58,390 | -42,850 | -49,970 |
| Net Income Growth | +30.44% | -2.23% | -36.27% | +14.25% | +9.52% |
Milestone Pharmaceuticals Inc (MIST)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.9000 -0.0500 (-2.56%) 03/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.9101 +0.0101 (+0.53%) 19:59 ET
for Fri, Mar 21st, 2025
Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montr'al, Canada.
Fiscal Year End Date: 12/31